Onconetix (ONCO) Cash from Operations (2021 - 2026)

Onconetix (ONCO) has reported Cash from Operations for 6 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 36.0% year-over-year to -$1.9 million in Q2 2026; TTM through Jun 2026 was -$10.3 million, a 88.7% decrease from a year earlier, with the FY2025 full-year figure at -$9.7 million, up 7.58% from the prior year.
• Cash from Operations was -$1.9 million for Q2 2026 at Onconetix, up from -$2.1 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$886091.0 in Q1 2022 and troughed at -$5.2 million in Q1 2024.
• A 5-year average of -$2.6 million and a median of -$2.5 million in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 729.29% in 2022 and surged 78.72% in 2024, its largest moves.
• Over 5 years, Cash from Operations stood at -$2.8 million in 2022, then slumped by 53.99% to -$4.3 million in 2023, then surged by 78.72% to -$917647.0 in 2024, then tumbled by 237.82% to -$3.1 million in 2025, then surged by 38.13% to -$1.9 million in 2026.
• The last three Cash from Operations figures came in at -$1.9 million (Q2 2026), -$2.1 million (Q1 2026), and -$3.1 million (Q4 2025), per Business Quant data.